News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Seehra Jasbir
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/25/2022 |
4
| Seehra Jasbir (CEO) has filed a Form 4 on Keros Therapeutics, Inc.|
Txns:
| Granted 165,000 options to buy
@ $46.3, valued at
$7.6M
|
|
| 05/20/2021 |
4
| Seehra Jasbir (Director) has filed a Form 4 on Eloxx Pharmaceuticals, Inc.|
Txns:
| Granted 20,000 options to buy
@ $1.48, valued at
$29.6k
|
|
| 01/12/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/22/2020 |
4
| Seehra Jasbir (Director) has filed a Form 4 on Eloxx Pharmaceuticals, Inc.|
Txns:
| Granted 20,000 options to buy
@ $3.39, valued at
$67.8k
|
|
| 04/13/2020 |
4
| Seehra Jasbir (CEO) has filed a Form 4 on Keros Therapeutics, Inc.|
Txns:
| Converted 11,169 shares
@ $0
Bought 20,000 shares
@ $16, valued at
$320k
Converted 11,169 preferred shares
@ $0 |
|
| 04/08/2020 |
4
| Seehra Jasbir (CEO) has filed a Form 4 on Keros Therapeutics, Inc.|
Txns:
| Granted 696,569 options to buy
@ $16, valued at
$11.1M
|
|
| 05/29/2019 |
4
| Seehra Jasbir (Director) has filed a Form 4 on Eloxx Pharmaceuticals, Inc.|
Txns:
| Granted 20,000 options to buy
@ $9.02, valued at
$180.4k
|
|
| 06/19/2018 |
4
| Seehra Jasbir (Director) has filed a Form 4 on Eloxx Pharmaceuticals, Inc.|
Txns:
| Granted 40,000 options to buy
@ $23.27, valued at
$930.8k
|
|
|
|